388 related articles for article (PubMed ID: 15623659)
21. Identification of a membrane-associated folate-binding protein in human leukemic CCRF-CEM cells with transport-related methotrexate resistance.
Jansen G; Westerhof GR; Kathmann I; Rademaker BC; Rijksen G; Schornagel JH
Cancer Res; 1989 May; 49(9):2455-9. PubMed ID: 2706633
[TBL] [Abstract][Full Text] [Related]
22. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G
Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783
[TBL] [Abstract][Full Text] [Related]
23. Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors.
Jansen G; Schornagel JH; Westerhof GR; Rijksen G; Newell DR; Jackman AL
Cancer Res; 1990 Dec; 50(23):7544-8. PubMed ID: 2253202
[TBL] [Abstract][Full Text] [Related]
24. Molecular basis of antifolate resistance.
Assaraf YG
Cancer Metastasis Rev; 2007 Mar; 26(1):153-81. PubMed ID: 17333344
[TBL] [Abstract][Full Text] [Related]
25. The relationship between folate transport activity at low pH and reduced folate carrier function in human Huh7 hepatoma cells.
Zhao R; Hanscom M; Goldman ID
Biochim Biophys Acta; 2005 Aug; 1715(1):57-64. PubMed ID: 16109384
[TBL] [Abstract][Full Text] [Related]
26. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.
Rhee MS; Galivan J; Wright JE; Rosowsky A
Mol Pharmacol; 1994 Apr; 45(4):783-91. PubMed ID: 7514264
[TBL] [Abstract][Full Text] [Related]
27. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance.
Jansen G; Mauritz R; Drori S; Sprecher H; Kathmann I; Bunni M; Priest DG; Noordhuis P; Schornagel JH; Pinedo HM; Peters GJ; Assaraf YG
J Biol Chem; 1998 Nov; 273(46):30189-98. PubMed ID: 9804775
[TBL] [Abstract][Full Text] [Related]
28. Differential usage of the transport systems for folic acid and methotrexate in normal human T-lymphocytes and leukemic cells.
Biswal BK; Verma RS
J Biochem; 2009 Nov; 146(5):693-703. PubMed ID: 19692428
[TBL] [Abstract][Full Text] [Related]
29. Variable expression of RFC1 in human leukemia cell lines resistant to antifolates.
Kobayashi H; Takemura Y; Ohnuma T
Cancer Lett; 1998 Feb; 124(2):135-42. PubMed ID: 9500202
[TBL] [Abstract][Full Text] [Related]
30. Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate.
Li WW; Tong WP; Bertino JR
Clin Cancer Res; 1995 Jun; 1(6):631-6. PubMed ID: 9816025
[TBL] [Abstract][Full Text] [Related]
31. Preservation of folate transport activity with a low-pH optimum in rat IEC-6 intestinal epithelial cell lines that lack reduced folate carrier function.
Wang Y; Rajgopal A; Goldman ID; Zhao R
Am J Physiol Cell Physiol; 2005 Jan; 288(1):C65-71. PubMed ID: 15385270
[TBL] [Abstract][Full Text] [Related]
32. Functional aspects of membrane folate receptors in human breast cancer cells with transport-related resistance to methotrexate.
Pinard MF; Jolivet J; Ratnam M; Kathmann I; Molthoff C; Westerhof R; Schornagel JH; Jansen G
Cancer Chemother Pharmacol; 1996; 38(3):281-8. PubMed ID: 8646804
[TBL] [Abstract][Full Text] [Related]
33. Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis.
Jansen G; van der Heijden J; Oerlemans R; Lems WF; Ifergan I; Scheper RJ; Assaraf YG; Dijkmans BA
Arthritis Rheum; 2004 Jul; 50(7):2130-9. PubMed ID: 15248210
[TBL] [Abstract][Full Text] [Related]
34. An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents.
Calvert H
Semin Oncol; 1999 Apr; 26(2 Suppl 6):3-10. PubMed ID: 10598549
[No Abstract] [Full Text] [Related]
35. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.
Shih C; Chen VJ; Gossett LS; Gates SB; MacKellar WC; Habeck LL; Shackelford KA; Mendelsohn LG; Soose DJ; Patel VF; Andis SL; Bewley JR; Rayl EA; Moroson BA; Beardsley GP; Kohler W; Ratnam M; Schultz RM
Cancer Res; 1997 Mar; 57(6):1116-23. PubMed ID: 9067281
[TBL] [Abstract][Full Text] [Related]
36. Decreased expression of the reduced folate carrier and folypolyglutamate synthetase is the basis for acquired resistance to the pemetrexed antifolate (LY231514) in an L1210 murine leukemia cell line.
Wang Y; Zhao R; Goldman ID
Biochem Pharmacol; 2003 Apr; 65(7):1163-70. PubMed ID: 12663051
[TBL] [Abstract][Full Text] [Related]
37. Determinants of activity of the antifolate thymidylate synthase inhibitors Tomudex (ZD1694) and GW1843U89 against mono- and multilayered colon cancer cell lines under folate-restricted conditions.
Peters GJ; Smitskamp-Wilms E; Smid K; Pinedo HM; Jansen G
Cancer Res; 1999 Nov; 59(21):5529-35. PubMed ID: 10554030
[TBL] [Abstract][Full Text] [Related]
38. Thymidylate synthase as a target for growth inhibition in methotrexate-sensitive and -resistant human head and neck cancer and leukemia cell lines.
McGuire JJ; Magee KJ; Russell CA; Canestrari JM
Oncol Res; 1997; 9(3):139-47. PubMed ID: 9220499
[TBL] [Abstract][Full Text] [Related]
39. Novel 6,5-fused ring heterocyclic antifolates: biochemical and biological characterization.
McGuire JJ; Bergoltz VV; Heitzman KJ; Haile WH; Russell CA; Bolanowska WE; Kotake Y; Haneda T; Nomura H
Cancer Res; 1994 May; 54(10):2673-9. PubMed ID: 8168096
[TBL] [Abstract][Full Text] [Related]
40. Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines.
Smith PG; Marshman E; Calvert AH; Newell DR; Curtin NJ
Semin Oncol; 1999 Apr; 26(2 Suppl 6):63-7. PubMed ID: 10598557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]